title: Concomitant radiation-doxorubicin administration in locally advanced and/or metastatic soft tissue sarcomas: preliminary results.
abstract: Doxorubicin was administered by continuous infusion at a dosage of 12 mg/sqm/day for 5 days concomitantly with radiation treatment (150 or 200 cGy/day for trunk or extremity lesions, respectively) for 5 days. The 5-day cycles were repeated every 3 weeks. Seventeen patients, 5 of whom were pretreated, entered the study; all were assessable for toxicity and 15 for response. The overall objective response rate was 46% (7/15): 1 complete and 6 partial responses. Response rate reached 54% in only non-pretreated patients (6/11) and 75% in patients with PS less than or = 2 (6/8). No disease progression was observed during treatment. The median duration of complete or partial responses was 28 weeks (range 5-86). Toxicity was low and treatment very well tolerated. In our preliminary analysis, the response rate obtained with this combined chemo-radiotherapic regimen was encouraging and the toxicity was acceptable.
authors.affiliation: Division of Medical Oncology, Genoa University, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Toma
authors.forename: R
authors.initials: R
authors.lastname: Palumbo
authors.forename: G
authors.initials: G
authors.lastname: Sogno
authors.forename: G
authors.initials: G
authors.lastname: Canavese
authors.forename: S
authors.initials: S
authors.lastname: Barra
authors.forename: C
authors.initials: C
authors.lastname: Marziano
authors.forename: J
authors.initials: J
authors.lastname: Serrano
authors.forename: E
authors.initials: E
authors.lastname: Albanese
authors.forename: R
authors.initials: R
authors.lastname: Rosso
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D004317:Doxorubicin